<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002247</url>
  </required_header>
  <id_info>
    <org_study_id>SUSTAIN CSX</org_study_id>
    <nct_id>NCT02002247</nct_id>
  </id_info>
  <brief_title>SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).</brief_title>
  <acronym>SUSTAINCSX</acronym>
  <official_title>SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). A Multicentre Randomized Controlled Trial of High Dose Sodium-selenite Administration in High Risk Cardiac Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daren K. Heyland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>biosyn Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Evaluation Research Unit at Kingston General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigators' research program is to investigate the effects of perioperative
      high dose selenium supplementation in high-risk cardiac surgical patients undergoing
      complicated open heart surgery. The investigators hypothesize that the therapeutic strategy
      tested in this randomized trial may contribute to a fewer complications, less organ injury
      and fewer deaths. Before the investigators conducted the large definitive trial, they
      conducted a pilot study to assess the feasibility of the protocol, and are rolling the pilot
      patients into the definitive trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over a million patients undergo open heart surgery annually and this number is likely to
      accelerate as the population ages and the prevalence of diabetes and cardiovascular disease
      continue to increase. Unfortunately, death, organ failure, and other serious complications
      are all too frequent following open heart surgery, especially in some high-risk patient
      populations.

      Selenium is a trace element that is important for many of the body's regulatory and metabolic
      functions especially during times of stress. International members of the study team have
      shown in a non-randomized study that high dose selenium supplementation was associated with
      improved clinical outcomes compared to a historical control group. The next step in this
      program of research is to conduct a randomized trial.

      The aim of this research program is to investigate the effects of perioperative high dose
      selenium supplementation in high-risk cardiac surgical patients undergoing complicated open
      heart surgery. The investigators hypothesize that the therapeutic strategy tested in this
      randomized trial may contribute to fewer complications, less organ injury and fewer deaths.

      The investigators propose to conduct a randomized, placebo-controlled, double-blind,
      multicentre definitive trial of 1400 patients across 20 sites in Germany and Canada, which
      will include the pilot study patients. An industry partner (Biosyn) will provide the product
      and some additional support for the European sites. Patients will be randomized to receive
      either a daily perioperative high-dose selenium or placebo until postoperative day 10
      (maximum) or upon earlier discharge from ICU. If the hypothesis is proven true, and this
      simple, inexpensive nutrient reduces complications and improves recovery of patients
      undergoing cardiac surgery, there is the potential to dramatically change clinical practice
      and improve health outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PODS free days + alive</measure>
    <time_frame>30 Day</time_frame>
    <description>Evaluate the PODS free days + alive as the primary outcome for the large-scale Phase III trial. We define PODS as the need for life-sustaining therapies (mechanical ventilation, vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or intermittent hemodialysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-Day Mortality</measure>
    <time_frame>30 Day</time_frame>
    <description>Mortality 30 days post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Acquired Infections</measure>
    <time_frame>30 day</time_frame>
    <description>To be evaluated up to 6 months post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative hemodynamic profile</measure>
    <time_frame>6 months</time_frame>
    <description>This includes: mean arterial blood pressure, cardiac power index, systemic vascular resistance, etc... To be assessed up to 6-months post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Complications</measure>
    <time_frame>6-months</time_frame>
    <description>This includes: arrhythmias, cardiac arrest, infarction. To be assessed up to 6-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>6-months</time_frame>
    <description>To be assessed up to 6-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative delirium</measure>
    <time_frame>6-months</time_frame>
    <description>Assessed by CAM-ICU score. To be assessed up to 6-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of stay</measure>
    <time_frame>6-months</time_frame>
    <description>To be assessed up to 6 months post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Re-admission Rates</measure>
    <time_frame>6-months</time_frame>
    <description>To be assessed up to 6-months post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of stay</measure>
    <time_frame>6-months</time_frame>
    <description>To be assessed up to 6 months post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Month Survival</measure>
    <time_frame>6-months</time_frame>
    <description>To be assessed at 6 months post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6-months</time_frame>
    <description>Health related quality of life to be assessed up to 6-months post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to work</measure>
    <time_frame>6-months</time_frame>
    <description>Assessed using a questionnaire to determine the patient's ability to return to their pre-operative working capabilities. To be assessed up to 6 months post-randomization.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Laboratory outcomes</measure>
    <time_frame>POD 10</time_frame>
    <description>To be assessed up to post-operative day (POD) 10 in patients who consent to this optional blood work.
To assess the potential effects of supplementation on selenium levels, safety parameters and other mechanistic markers. Whole blood levels of selenium, selenoprotein P (Sel-P), antibodies against oxidized LDL, markers of inflammation (interleukin[IL]-6, IL-10, TNF alpha) and activity of glutathione-peroxidase (GPx) will be assessed to determine the efficacy of selenium supplementation in these patients.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium selenite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose sodium-selenite will be administered to subjects intravenously:
1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium selenite</intervention_name>
    <description>All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.</description>
    <arm_group_label>sodium selenite</arm_group_label>
    <other_name>selenium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 years of age)

          -  Scheduled to undergo elective or urgent cardiac surgery with the use of
             cardiopulmonary bypass (CPB) and cardioplegic arrest that exhibit a high perioperative
             risk profile as defined by the presence of one or more of the following:

               -  a) Planned valve surgery combined with CABG or multiple valve replacement/repair
                  surgeries or combined cardiac surgical procedures involving the thoracic aorta;

               -  b) Any cardiac surgery with a high perioperative risk profile, defined as a
                  predicted operative mortality of ≥ 5% (EuroSCORE II).

        Exclusion Criteria:

        We will exclude patients who meet any of the following criteria:

          -  Known hypersensitivity to sodium-selenite or to any of the constituents of the
             solution.

          -  Renal failure requiring dialysis at the point of screening.

          -  Chronic liver disease as evidenced by a pre-operative total bilirubin &gt;2 mg/dl or 34
             umol/L.

          -  Disabling neuropsychiatric disorders (severe dementia, severe Alzheimer's disease,
             advanced Parkinson's disease).

          -  Pregnancy or lactation period.

          -  Simultaneous participation in another clinical trial of an experimental therapy
             (co-enrolment acceptable in observational studies or randomized trials of existing
             therapies if permitted by both steering committees and local ethics boards).

          -  Patients undergoing heart transplantation or preoperative planned LVAD insertion or
             complex congenital heart surgery.

          -  Family members of investigators (required by German Regulatory Authorities).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daren K Heyland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Stoppe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH Aachen University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard J McDonald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daren K Heyland, MD</last_name>
    <phone>613-549-6666</phone>
    <phone_ext>4847</phone_ext>
    <email>dkh2@queensu.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitlock Richard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Jones, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard J McDonald, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernard J McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Fremes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Fowler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mazer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Parotto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cardiologie de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1C1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoan Lamarche, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yoan Lamarche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Cameron, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roupen Hatzakorzian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sacre Coeur</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoan Lamarche, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siamak Mohammadi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen University Hospital</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Stoppe, MD</last_name>
      <phone>0049-024108036575</phone>
      <email>cstoppe@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Stoppe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Wittman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Meybohm, MD</last_name>
      <phone>: 069/ 6301 - 5998</phone>
      <email>patrick.meybohm@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Patrick Meybohm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Her- und Gefäßchirurgie Universitäts-Herzzentrum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Trummer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Herz-, Kinderherz- und Gefäßchirurgie UKGM Giessen</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Niemann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Elke, MD</last_name>
      <phone>+49 431 5972991</phone>
      <email>gunnar.elke@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Herz- und Thoraxchirurgie Uniklinik Köln</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Liakopoulos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Laufenberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erich Kilger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie Universitätsmedizin Münster, Zentralklinikum</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ermert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH Universitätsklinik für Anästhesiologie / Intensivmedizin / Notfallmedizin / Schmerztherapie</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malte Book, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas Grote, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Anästhesiologie und Intensivtherapie Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Kletzin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>November 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Evaluation Research Unit at Kingston General Hospital</investigator_affiliation>
    <investigator_full_name>Daren K. Heyland</investigator_full_name>
    <investigator_title>Scientific Director</investigator_title>
  </responsible_party>
  <keyword>antioxidants</keyword>
  <keyword>selenium</keyword>
  <keyword>heart disease</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>perioperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Selenious Acid</mesh_term>
    <mesh_term>Sodium Selenite</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

